Op-ed: Pharma must show courage, leadership on public health

Pharma companies can't claim to care about global patient wellbeing unless they stand up to Trump's public health cuts.

Meeting patients where they are: Improving bipolar I disorde...

As a psychiatric provider working with people from all walks of life, I’ve seen how serious mental health conditions, particularly bipolar I disorder (BD-I), can present differently dependi

Prevention for a healthier, more productive society

During Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine.

How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

Direct-to-patient is more than just telehealth – with EVERSA...

Unifying observational research with a next-generation virtu...

Observational research is core to drug development, helping researchers understand the natural history of diseases and the real-world impact of treatments on patients.